[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"probiotics\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:probiotics":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,43,86,111,125,152,179,205,230,259,288],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100605809","phase-4-the-effect-of-oral-clostridium-butyricum-on-the-recurrence-after-colonoscopic-resection-of-colorectal-adenoma-100605809",false,"NCT07167342","The Effect of Oral Clostridium Butyricum on the Recurrence After Colonoscopic Resection of Colorectal Adenoma","The Effect of Oral Clostridium Butyricum on the Recurrence After Colonoscopic Resection of Colorectal Adenoma - A Multicenter, Double-blinded, Differential Design, Randomized, Placebo-controlled Study","Inclusion Criteria:\n\n* Age between 18 and 75 years\n* No restriction on sex\n* Boston Bowel Preparation Score (BBPS) ≥ 7 prior to endoscopic procedure\n* Completed endoscopic resection of colorectal adenomas (including cold snare polypectomy, ESD, EMR, etc.) with no residual adenomas or polyps observed endoscopically\n* Histologically confirmed adenomas (including tubular, villous, or tubulovillous types) without malignant transformation\n* Able to take oral medication\n* Signed informed consent\n\nExclusion Criteria:\n\n* Use of probiotics, prebiotics, synbiotics, or antibiotics within 2 weeks prior to enrollment\n* Presence of psychiatric disorders or other conditions preventing compliance with the intervention\n* Dysfunction of vital organs (liver, kidney, heart, etc.) deemed unsuitable for clinical study participation after evaluation\n* Participation in other clinical trials within 3 months prior to enrollment\n* History of gastrointestinal surgery (excluding endoscopic procedures)\n* History of inflammatory bowel disease\n* History of autoimmune diseases\n* Long-term use of aspirin (≥100 mg\u002Fday for over 3 months) or calcium supplements (≥1200 mg\u002Fday for over 3 months)\n* Pregnancy or breastfeeding\n* Previous treatment for colorectal adenomas (including endoscopic or surgical resection)\n* Familial adenomatous polyposis (FAP)","ALL","18 Years","75 Years",{"count":20,"type":21},294,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","The prevention of recurrence after colorectal adenoma resection remains an urgent medical issue to be addressed. Previous studies have mainly focused on nonsteroidal anti-inflammatory drugs, calcium supplements, and vitamins. The gut microbiota and its metabolic products are believed to play a potential role in the development and progression of colorectal adenomas. Clostridium butyricum, a butyrate-producing probiotic, has not yet been studied for its potential in preventing the recurrence of colorectal adenomas following resection. Therefore, this study, designed as a multicenter, double-blind, placebo-controlled randomized controlled trial, aims to explore evidence-based data on the role of Clostridium butyricum in preventing colorectal adenoma recurrence.",[27,28],"Colorectal Adenoma","Probiotics",[27,30],"Clostridium butyricum","RECRUITING","2026-05-22",{"date":34,"type":35},"2026-05-26","ACTUAL",{"date":32,"type":35},{"date":38,"type":21},"2030-04-30",{"name":40,"class":41},"The Affiliated Hospital of Qingdao University","OTHER",2,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":51,"minAge":17,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":56,"conditions":57,"keywords":64,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":85},"100595200","effectiveness-of-coenzyme-q10-and-probiotics-in-periodontal-therapy-during-pregnancy-100595200","NCT07029360","Effectiveness of Coenzyme Q10 and Probiotics in Periodontal Therapy During Pregnancy","Adjunctive Use of Coenzyme Q10 and Probiotics to Improve Periodontal Health in Pregnant Women: A Randomized Controlled Trial","PREG-Q10","Inclusion Criteria:\n\n* Pregnant women between the 4th and 8th month of gestation\n* Age ≥ 18 years\n* Able to understand and communicate in Italian and\u002For English\n* Willing to provide written informed consent\n* Good compliance and willingness to follow study instructions\n\nExclusion Criteria:\n\n* Presence of cardiac pacemakers\n* Diagnosed psychological, neurological, or psychiatric disorders\n* Ongoing oncological therapy\n* Use of bisphosphonates within the last 12 months\n* Poor motivation or low compliance\n* Substance abuse (drugs or alcohol) or lifestyle incompatible with study requirements","FEMALE",{"count":53,"type":21},40,[55],"NA","This randomized controlled clinical trial aims to evaluate the effectiveness of adjunctive coenzyme Q10 and probiotic supplementation (Limosilactobacillus reuteri Prodentis®) in improving periodontal health in pregnant women undergoing non-surgical periodontal therapy. Forty participants will be randomly assigned to two groups: the test group will receive professional oral hygiene every three months along with a coenzyme Q10-based toothpaste and daily probiotic supplementation; the control group will follow the same protocol without probiotics. The primary outcome is the reduction of the Plaque Index (PI), while secondary outcomes include Bleeding on Probing (BoP), Probing Pocket Depth (PPD), Clinical Attachment Level (CAL), gingival inflammation (MGI, PMGI), plaque distribution (PCR%, API), and gingival recession (R). The study duration is 6 months. The goal is to assess whether this combined therapy can promote a balanced oral microbiota and enhance periodontal health during pregnancy.",[58,59,60,61,28,62,63],"Pregnancy","Periodontal Disease","Gingivitis","Dental Plaque","Coenzyme Q10","Microbiota",[65,66,62,61,67,60,68,63,69,70,71,72,73,58,74,28,75],"Bleeding on Probing","Clinical Attachment Loss","Gingival Inflammation","Limosilactobacillus reuteri","Non-Surgical Periodontal Treatment","Oral Microbiota","Periodontal Therapy","Plaque Control","Plaque Index","Pregnant Women","Randomized Controlled Trial","2026-02-19",{"date":78,"type":35},"2026-02-20",{"date":80,"type":35},"2025-07-01",{"date":82,"type":21},"2026-06-10",{"name":84,"class":41},"University of Pavia",1,{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":4,"eligibilityCriteria":92,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":93,"enrollmentInfo":94,"targetDuration":4,"studyType":22,"phases":96,"briefSummary":97,"conditions":98,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":85},"100607356","phase-4-efficacy-of-bacillus-coagulans-in-alleviating-anxiety-and-depression-in-patients-with-functional-dyspepsia-100607356","NCT07187492","Efficacy of Bacillus Coagulans in Alleviating Anxiety and Depression in Patients With Functional Dyspepsia","Efficacy of Bacillus Coagulans in Alleviating Anxiety and Depression in Patients With Functional Dyspepsia：A Prospective, Double-Blind, Randomized, Placebo-Controlled Clinical Trial","Inclusion Criteria:\n\n* Patients diagnosed with functional dyspepsia (FD) according to the Rome IV criteria.\n* Aged 18 to 80 years, regardless of gender.\n* Hospital Anxiety and Depression Scale (HADS) score between 8 and 14.\n\nExclusion Criteria:\n\n* Use of probiotics or antibiotics within one month prior to the trial.\n* Use of psychoactive medications (including hypnotics, sedatives, anxiolytics, or antidepressants) within one month prior to the trial.\n* Use of hormones, immunosuppressants, or cytotoxic agents within one month prior to the trial.\n* Participation in any other clinical trial within one month prior to the study.\n* Positive test for Helicobacter pylori (Hp) infection.\n* Long-term use of traditional Chinese herbal medicine.\n* Pregnancy or lactation.\n* History of drug abuse.\n* Comorbidities such as irritable bowel syndrome (IBS), gastroesophageal reflux disease (GERD), functional constipation (FC), or other significant conditions that may interfere with the trial-including severe hepatic, renal, respiratory, or autoimmune disorders; bleeding diatheses; psychiatric diseases; endocrine disorders; etc.\n* History of major surgery or diagnosis of diabetes mellitus.\n* Refusal to provide written informed consent.","80 Years",{"count":95,"type":21},180,[24],"Objective: This study aims to evaluate the effectiveness of Bacillus coagulans in improving anxiety and depression in patients diagnosed with functional dyspepsia according to the Rome IV criteria.\n\nMethods: This trial plans to enroll 180 patients (90 per group). The study will employ a double-blind design. For patients diagnosed with FD according to the Rome IV criteria, in addition to conventional treatment (treated with Mosapride Citrate Tablets (Guangdong Anno Guocai) for Postmeal Discomfort Syndrome (PDS) and Esomeprazole Enteric Coated Tablets (Shijiazhuang Longze Pharmaceutical Guocai) for Upper Abdominal Pain Syndrome (EPS)), the experimental group was treated with Bacillus coagulans, while the control group received a placebo with the same appearance and odor.\n\nThe treatment intervention will last for 4 weeks. The main indicator of this experiment is the improvement of the Hospital Anxiety and Depression Scale (HADS score) after 4 weeks of treatment. The secondary indicators are the improvement rate of the overall treatment effectiveness evaluation questionnaire (OTE questionnaire), the improvement of the global overall symptom score (GOS score), the improvement of the simplified Nipin scale (SF-NDI), and the improvement of the Pittsburgh Sleep Index (PSQI) after 4 weeks of treatment. Upon completion of the trial, the patients' conditions will be re-evaluated, and treatment plans will be adjusted accordingly.",[99,28,100,101],"Functional Dyspepsia","Depression","Anxiety","2025-12-29",{"date":104,"type":35},"2026-01-05",{"date":106,"type":35},"2025-09-20",{"date":108,"type":21},"2027-05-31",{"name":110,"class":41},"Xijing Hospital of Digestive Diseases",{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":4,"eligibilityCriteria":92,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":93,"enrollmentInfo":117,"targetDuration":4,"studyType":22,"phases":118,"briefSummary":119,"conditions":120,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":121,"startDateStruct":122,"completionDateStruct":123,"leadSponsor":124,"locationsCount":85},"100607002","phase-4-efficacy-of-clostridium-butyricum-in-alleviating-anxiety-and-depression-in-patients-with-functional-dyspepsia-100607002","NCT07182890","Efficacy of Clostridium Butyricum in Alleviating Anxiety and Depression in Patients With Functional Dyspepsia","Efficacy of Clostridium Butyricum in Alleviating Anxiety and Depression in Patients With Functional Dyspepsia：A Prospective, Double-Blind, Randomized, Placebo-Controlled Clinical Trial",{"count":95,"type":21},[24],"Objective: This study aims to evaluate the effectiveness of Clostridium butyricum in improving anxiety and depression in patients diagnosed with functional dyspepsia according to the Rome IV criteria.\n\nMethods: This trial plans to enroll 180 patients (90 per group). The study will employ a double-blind design. For patients diagnosed with FD according to the Rome IV criteria, in addition to conventional treatment (treated with Mosapride Citrate Tablets (Guangdong Anno Guocai) for Postmeal Discomfort Syndrome (PDS) and Esomeprazole Enteric Coated Tablets (Shijiazhuang Longze Pharmaceutical Guocai) for Upper Abdominal Pain Syndrome (EPS)), the experimental group was treated with Clostridium butyricum, while the control group received a placebo with the same appearance and odor.\n\nThe treatment intervention will last for 4 weeks. The main indicator of this experiment is the improvement of the Hospital Anxiety and Depression Scale (HADS score) after 4 weeks of treatment. The secondary indicators are the improvement rate of the overall treatment effectiveness evaluation questionnaire (OTE questionnaire), the improvement of the global overall symptom score (GOS score), the improvement of the simplified Nipin scale (SF-NDI), and the improvement of the Pittsburgh Sleep Index (PSQI) after 4 weeks of treatment. Upon completion of the trial, the patients' conditions will be re-evaluated, and treatment plans will be adjusted accordingly.",[99,28,100,101],{"date":104,"type":35},{"date":106,"type":35},{"date":108,"type":21},{"name":110,"class":41},{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":131,"eligibilityCriteria":132,"healthyVolunteers":11,"sex":16,"minAge":133,"maxAge":134,"enrollmentInfo":135,"targetDuration":4,"studyType":22,"phases":137,"briefSummary":138,"conditions":139,"keywords":4,"overallStatus":142,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":4},"100592218","phase-4-impact-of-probiotics-on-antibiotic-associated-diarrhea-in-community-acquired-pneumonia-100592218","NCT06990568","Impact of Probiotics on Antibiotic-associated Diarrhea in Community-acquired Pneumonia","The Effect of Probiotic Administration on the Incidence of Antibiotic-associated Diarrhea in Patients With Community-acquired Pneumonia","PROBIO","Inclusion Criteria:\n\n* Adult patients aged 19 years or older admitted with a diagnosis of community-acquired pneumonia\n* Patients eligible for oral medication administration (able to take oral or enteral feeding)\n\nExclusion Criteria:\n\n* Sepsis patients\n* Patients admitted to the intensive care unit (ICU) following endotracheal intubation\n* Elderly patients aged 80 years or older\n* Pregnant women\n* Patients who have diarrhea at the time of admission\n* Patients with a history of using probiotics within 3 months prior to admission\n* Patients with a history of using laxatives within 1 week prior to admission\n* Patients suspected of being in shock (mean arterial pressure \\\u003C 65 mmHg) at the time of admission","19 Years","79 Years",{"count":136,"type":21},100,[24],"The study goal is to determine whether oral administration of a probiotic mixture can reduce the incidence of antibiotic-associated diarrhea in patients with community-acquired pneumonia.",[140,28,141],"Pneumonia","Diarrhea","NOT_YET_RECRUITING","2025-05-23",{"date":145,"type":35},"2025-05-25",{"date":147,"type":21},"2025-06-01",{"date":149,"type":21},"2026-12-31",{"name":151,"class":41},"National Health Insurance Service Ilsan Hospital",{"id":153,"slug":154,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":4,"eligibilityCriteria":158,"healthyVolunteers":11,"sex":16,"minAge":159,"maxAge":4,"enrollmentInfo":160,"targetDuration":4,"studyType":22,"phases":162,"briefSummary":163,"conditions":164,"keywords":166,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":85},"100592852","the-effect-of-survival-response-and-microbiota-change-in-different-therapy-under-probiotic-supplement-100592852","NCT06998823","The Effect of Survival, Response and Microbiota Change in Different Therapy Under Probiotic Supplement","The Effect of Survival, Response and Microbiota Change in Different Therapy Under Probiotic Supplement (Clostridium Butyricum) in Patient With Malignant Tumor","Inclusion Criteria:\n\n1. age≧20\n2. participants with cancer therapy and agree to sign informed consent\n3. Cancer confirmed by clinical or pathological diagnosis\n\nExclusion Criteria:\n\n1. age\\\u003C20\n2. Pregnant or breastfeeding women","20 Years",{"count":161,"type":21},120,[55],"Probiotics are a group of viable microorganisms including bacteria and yeasts that if consumed in sufficient amounts, may afford health benefits to the host. The major advantage of probiotic administration is its ability to maintain gut microbial homeostasis, reduce pathogenic microorganisms in the GI tract, and restores homeostasis of intestinal microorganisms. Moreover, by modulating microbiota and immune responses, decreasing bacterial translocation, promoting the function of the gut barrier, inducing anti- inflammatory properties, triggering anti-pathogenic activity, and decreasing tumor development and metastasis, probiotics might contribute to the prevention and treatment of GI cancers and lung cancer. Considering the potential roles of Helicobacter pylori (H. pylori) in the initiation of colorectal and gastric cancers, the possible properties of probiotics against GI neoplasm in humans have been investigated in relation to their suppressive effects on H. pylori. The gut microbiota also has proved to in the response and resistance to immunotherapy. By triggering immune activity, probiotics, as functional dietary supplements, may mitigate neoplastic predisposition and development of GI cancers. Clostridium butyricum is a spore-forming bacillus named for its capacity to produce high amounts of butyric acid and is found in soil. Clostridium butyricum MIYAIRI 588 strain (MIYA-BM) is widely used as probiotic therapy to improve symptoms related to dysbiosis such as constipation, nonantimicrobial diarrhea, and anti- microbial-associated diarrhea in Japan and China. Clostridium butyricum increases beneficial bacteria, especially lactobacilli and bifidobacteria. Bifidobacterium promotes antitumor immunity and facilitates efficacy of antitumor treatment. The antitumor treatments are differed to three types: immune checkpoint blockade, target therapy and chemotherapy. Thus, investigators hypothesized that probiotic Clostridium butyricum therapy (CBT) may enhance the therapeutic efficacy of anti-tumor therapy through the modulation of gut microbiota. Investigators will discuss the different kinds of anti-tumor effect in survival and response after probiotic supplement.",[28,165],"Cancer, Therapy-Related",[28,167,168,169],"Immunotherapy","Targeted Therapy","Chemotherapy","2025-05-22",{"date":172,"type":35},"2025-05-31",{"date":174,"type":35},"2024-03-20",{"date":176,"type":21},"2026-11-08",{"name":178,"class":41},"Chang Gung Memorial Hospital",{"id":180,"slug":181,"hasResults":11,"nctId":182,"briefTitle":183,"officialTitle":183,"acronym":184,"eligibilityCriteria":185,"healthyVolunteers":11,"sex":51,"minAge":4,"maxAge":186,"enrollmentInfo":187,"targetDuration":4,"studyType":22,"phases":188,"briefSummary":189,"conditions":190,"keywords":192,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":197,"startDateStruct":199,"completionDateStruct":201,"leadSponsor":203,"locationsCount":85},"100587513","the-role-of-probiotics-in-the-treatment-of-endometriosis-prometrios-a-randomised-double-blinded-placebo-controlled-cross-over-trial-100587513","NCT06929364","The Role of Probiotics in the Treatment of Endometriosis (ProMetrioS): a Randomised Double-blinded Placebo-controlled Cross-over Trial","ProMetrioS","Minimum Age: - Maximum Age: 35 Years Sex: Female Gender Based: Ye - only women can participate in this study Accepts Healthy Volunteers: No\n\nInclusion Criteria:\n\n* adult subjects with stage III or IV endometriosis diagnosis confirmed by biopsy\n\nExclusion Criteria:\n\n* Age \\> 35 years\n* Immunocompromised patients\n* Patients with chronic inflammatory diseases (e.g., autoimmune disorders)\n* Pregnancy\n* Use of supplements and foods with probiotics\n* Use of immunosuppressant, antibiotic, proton pump inhibitors and corticosteroid drugs\n* Use of probiotics product less than one month before start of study or during study","35 Years",{"count":53,"type":21},[55],"ProMetrioS is a randomised blinded placebo-controlled cross-over trial investigating the effect of specific multistrain probiotics in patients with endometriosis. The aim of this clinical trial is to determine whether probiotic treatment can significantly modulate gut microbiome composition and functionality in endometriosis patients, specifically parameters associated with the estrobolome.",[191,28],"Endometriosis",[193,194,195],"endometriosis","probiotics","microbiome","2025-04-14",{"date":198,"type":35},"2025-04-16",{"date":200,"type":35},"2024-11-01",{"date":202,"type":21},"2025-11-30",{"name":204,"class":41},"The Gut Microbiome Center (Centar za crijevni mikrobiom)",{"id":206,"slug":207,"hasResults":11,"nctId":208,"briefTitle":209,"officialTitle":210,"acronym":211,"eligibilityCriteria":212,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":213,"targetDuration":4,"studyType":22,"phases":215,"briefSummary":217,"conditions":218,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":221,"startDateStruct":223,"completionDateStruct":225,"leadSponsor":227,"locationsCount":229},"100585608","phase-2-probiotics-in-advanced-urothelial-carcinoma-100585608","NCT06904573","Probiotics in Advanced Urothelial Carcinoma","A Multicenter, Randomized Controlled Phase II Study of Evaluating the Efficacy and Safety of Immunotherapy Combined With Oral Probiotics Compound (Biolosion) in Patients With Advanced Urothelial Carcinoma","IMPROVE","Inclusion Criteria:\n\n* Patients included in this study must meet all of the following criteria:\n\n  1. Aged 18 or above;\n  2. Histologically or cytologically confirmed locally advanced inoperable (such as T4b, or N2-3) or metastatic urothelial carcinoma, including bladder, ureter, renal pelvis and urethra;\n  3. Patients who have received previous treatment with immune checkpoint inhibitors (PD-1\u002FPD-L1 monoclonal antibodies) are allowed;\n  4. According to RECIST1.1 standard, there is at least one measurable target lesion;\n  5. ECOG score ≤2;\n  6. Good bone marrow, kidney (serum creatinine clearance calculated by CG formula\\> 30 mL\u002Fmin), liver and coagulation function:\n  7. Expected survival period ≥ 6 months;\n  8. The patient understands the research procedures and signs the informed consent form in writing to indicate his\u002Fher agreement to participate in the study;\n  9. Female subjects of childbearing potential should have a negative urine or serum pregnancy test within 7 days before the first dose of study drug (Cycle 1, Day 1). If the urine pregnancy test result cannot be confirmed as negative, a blood pregnancy test is required.\n  10. If there is a risk of pregnancy, male and female patients should use highly effective contraception (i.e., a method with a failure rate of less than 1% per year) and continue for at least 180 days after stopping the trial treatment.\n\nExclusion Criteria:\n\n* Any of the following will be considered as meeting the exclusion criteria of the study:\n\n  1. Patients with locally advanced disease may receive local radical treatment;\n  2. History of clinically symptomatic cardiovascular, liver, respiratory, renal, hematoendocrine, or neuropsychiatric diseases;\n  3. Clear brain\u002Fmeningeal metastasis;\n  4. Peripheral neuropathy \\>1 degree;\n  5. Patients who have received anti-tumor monoclonal antibody treatment within 4 weeks before the start of the study, or have received other anti-tumor drug treatment and have not recovered from adverse events\u002Freactions;\n  6. Participated in any investigational drug treatment within 4 weeks before the start of treatment;\n  7. Patients who had received axial bone radiotherapy within 4 weeks before the start of the study or had not recovered from adverse reactions caused by previous radiotherapy;\n  8. Known severe allergic reaction to the study drug, its active ingredients and\u002For any excipients;\n  9. Patients diagnosed with immunodeficiency or receiving systemic glucocorticoids or any other form of immunosuppressive therapy within 7 days before the first dose of the study; physiological doses of glucocorticoids (≤10 mg\u002Fday of prednisone or equivalent drugs) are allowed;\n  10. Active autoimmune diseases requiring systemic treatment (such as the use of disease-modifying drugs, corticosteroids, or immunosuppressants) occurred within 2 years before the first dose. Replacement therapies (such as thyroxine, insulin, or physiological corticosteroids for adrenal or pituitary insufficiency) are not considered systemic treatment; a history of non-infectious pneumonia requiring glucocorticoid treatment within 1 year before the first dose or current interstitial lung disease;\n  11. Received solid organ or blood system transplantation;\n  12. Known history of human immunodeficiency virus (HIV) infection (i.e. HIV 1\u002F2 antibody positive). Untreated active hepatitis B;\n  13. Untreated active hepatitis B; Note: Hepatitis B subjects who meet the following criteria are also eligible for inclusion: HBV viral load must be \\\u003C1000 copies\u002Fml (200 IU\u002Fml) before the first dose, and subjects should receive anti-HBV treatment during the entire study chemotherapy treatment to avoid viral reactivation. For subjects with anti-HBc (+), HBsAg (-), anti-HBs (-), and HBV viral load (-), preventive anti-HBV treatment is not required, but viral reactivation needs to be closely monitored;\n  14. Subjects with active HCV infection (HCV antibody positive and HCV-RNA level above the detection limit) received live vaccine within 30 days before the first dose (Cycle 1, Day 1);\n  15. A history of other malignant tumors in the past 5 years, excluding cured non-malignant melanoma of the skin, cervical carcinoma in situ, and incidentally discovered prostate cancer (stage lower than T2N0M0, Gleason score \\\u003C7, or undetectable PSA);\n  16. Medical history or disease evidence, abnormal treatment or laboratory test values, or other conditions that the researcher considers unsuitable for enrollment that may interfere with the trial results or prevent the subject from fully participating in the study;\n  17. Breastfeeding women\n  18. People with chronic diseases who need to take antibiotics for a long time.",{"count":214,"type":21},222,[216],"PHASE2","This is a multicenter, randomized, controlled phase II Study of evaluating the efficacy and safety of immunotherapy combined with probiotics compound (Biolosion) in patients with advanced urothelial carcinoma.",[219,28,167],"Advanced Urothelial Carcinoma","2025-03-28",{"date":222,"type":35},"2025-04-01",{"date":224,"type":35},"2025-01-01",{"date":226,"type":21},"2028-01-01",{"name":228,"class":41},"Sun Yat-sen University",3,{"id":231,"slug":232,"hasResults":11,"nctId":233,"briefTitle":234,"officialTitle":235,"acronym":236,"eligibilityCriteria":237,"healthyVolunteers":238,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":239,"targetDuration":4,"studyType":22,"phases":241,"briefSummary":242,"conditions":243,"keywords":247,"overallStatus":142,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":251,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":257,"locationsCount":4},"100584573","effect-of-probiotic-and-synbiotic-administration-on-nutritional-status-in-hemodialysis-patients-100584573","NCT06891105","Effect of Probiotic and Synbiotic Administration on Nutritional Status in Hemodialysis Patients","Effect of Probiotic and Synbiotic Administration on the Nutritional Status of Hemodialysis Patients. a Randomized Controlled Trial","ProSyn-HD","Inclusion Criteria:\n\n* Patients with End-Stage Renal Disease (ESRD) on regular hemodialysis (3 times per week).\n* Age 18 years or older.\n* Not prepared for kidney transplantation for more than 1 year.\n* Able and willing to provide written informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Patients who are actively preparing for kidney transplantation.\n* Pregnant or breastfeeding women.\n* Patients with active malignancy or undergoing cancer treatment.\n* Patients with known structural gastrointestinal (GI) disease (e.g., inflammatory bowel disease, severe gastrointestinal motility disorders).\n* Patients who have severe infections or other severe conditions that might interfere with the study's assessments.\n* Patients with known allergies to probiotics or synbiotics.",true,{"count":240,"type":21},60,[55],"This study aims to investigate the impact of probiotics and synbiotics on the nutritional status of patients with end-stage kidney disease (ESRD) who are undergoing hemodialysis. ESRD patients often face challenges such as poor nutritional status, increased risk of infections, and imbalances in gut microbiota. These challenges are made worse by the frequent use of medications, dietary restrictions, and the hemodialysis process itself, which can disturb the gut's natural bacteria balance.\n\nProbiotics are live microorganisms that provide health benefits when taken in adequate amounts, while synbiotics are a combination of probiotics and prebiotics (substances that promote the growth of beneficial bacteria). The goal of this study is to explore whether supplementing ESRD patients with probiotics or synbiotics can improve their nutritional health, including aspects like body mass index (BMI), skin fold thickness, and protein metabolism.\n\nThe study will involve 60 patients from a hemodialysis center in Mansoura, Egypt. Patients will be randomly assigned to one of three groups: one group will receive probiotics, another will receive synbiotics, and the third group will act as a control (no treatment). The study will evaluate changes in nutritional markers and other health parameters before and after six months of supplementation.\n\nThis study hopes to provide insights into new, cost-effective interventions for improving the health of patients undergoing long-term dialysis treatment by addressing the question of whether these supplements can improve the nutritional status of hemodialysis patients.",[244,28,245,246],"Hemodialysis","Synbiotics","Nutritional Status",[248,244,28,245,246,249],"End-Stage Renal Disease","Gut Microbiota","2025-03-18",{"date":252,"type":35},"2025-03-24",{"date":254,"type":21},"2025-04-15",{"date":256,"type":21},"2025-11-01",{"name":258,"class":41},"Mansoura University",{"id":260,"slug":261,"hasResults":11,"nctId":262,"briefTitle":263,"officialTitle":263,"acronym":264,"eligibilityCriteria":265,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":266,"targetDuration":4,"studyType":22,"phases":268,"briefSummary":269,"conditions":270,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":279,"lastUpdatePostDateStruct":280,"startDateStruct":282,"completionDateStruct":284,"leadSponsor":286,"locationsCount":85},"100502342","phase-2-synbiotics-and-fecal-microbiota-transplantation-to-treat-non-alcoholic-steatohepatitis-100502342","NCT05821010","Synbiotics and Fecal Microbiota Transplantation to Treat Non-Alcoholic Steatohepatitis","SYNCH","Inclusion Criteria:\n\n* biopsy-proven NASH obtained up to 32 weeks before screening: SAF Steatosis score ≥1, Activity ≥2, Fibrosis \\\u003C4; 50% of participants should at least have NASH fibrosis stage 1, 2 or 3 according to the NASH CRN fibrosis staging system based on tandem reading of two expert liver pathologists\n* fluency in Dutch or English\n* participants should be able to understand the information and give informed consent\n\nExclusion Criteria:\n\n* Current or history of significant alcohol consumption for a period of more than 3 consecutive months within 1 year before screening (significant alcohol consumption is defined as more than 2 international units\u002Fday for females and more than 3 international units\u002Fday for males, on average; 1 international unit contains ±14 grams of alcohol)\n* liver cirrhosis or hepatocellular carcinoma\n* hepatitis B and\u002For C\n* auto-immune hepatitis\n* Wilson's disease\n* primary sclerosing cholangitis\n* primary biliary cholangitis\n* alpha-1-antitripsine deficiency and hemochromatosis\n* history of liver transplant, current placement on a liver transplant list\n* use of pre-, pro- or synbiotics\n* use of systemic antibiotics 3 month prior to randomization\n* use of tamoxifen, methotrexate or amiodarone\n* prior or planned bariatric surgery\n* active GLP-1 receptor agonist treated diabetes mellitus\n* bleeding disorder\n* International normalized ratio (INR) of prothrombin time \\>1.4 or platelet count \\\u003C100 109\u002FL at screening\n* anti-platelet\u002Fcoagulant therapy use which cannot be temporarily discontinued\n* any major cardiovascular event within 6 months prior to screening (e.g. myocardial infarction, cerebrovascular accident)\n* prolonged compromised immunity (e.g. recent cytotoxic chemotherapy, HIV-infection with a CD4 count \\\u003C 240)\n* active or prior history of invasive malignancy (except for curatively treated in situ carcinomas \\[e.g., cervix\\] or non-melanoma skin cancer) unless a complete remission was achieved\n* surgery scheduled for the trial duration period, except for minor surgical procedures, in the opinion of the investigator\n* pregnant or nursing women\n* any condition which, in the investigator's opinion, might jeopardize participants' safety or compliance with the protocol\n* participation in another concomitant clinical trial.",{"count":267,"type":21},48,[216],"The goal of this clinical trial is to investigate the therapeutic potential of A. soehngenii and pasteurized A. muciniphila combined with B. animalis subsp. lactis and fructo-oligosaccharides with and without conditioned vegan lyophilized fecal microbiota transplantation capsules to reduce NASH in patients with fibrotic NASH. The main questions to answer are:\n\n1. Can NASH be treated by altering the gut microbiota using LFMT capsules?\n2. Can NASH be treated using a syntrophic cocktail of synbiotics and will these strains strengthen the effect of FMT?\n3. What are the underlying mechanism by which the aforementioned treatments attenuate NASH?\n\nParticipants will be treated with FMT-capsules or placebo, and all participants will receive a cocktail of 3 strains of probiotics and one type of prebiotic.",[271,272,273,274,275,28,276,277,278],"Non Alcoholic Steatohepatitis","Non-Alcoholic Fatty Liver Disease","Fecal Microbiota Transplantation","FMT","Prebiotics","Microbiome","Intestinal Microbiome","Gut Microbiome","2024-08-26",{"date":281,"type":35},"2024-08-27",{"date":283,"type":35},"2023-03-17",{"date":285,"type":21},"2026-08-20",{"name":287,"class":41},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)",{"id":289,"slug":290,"hasResults":11,"nctId":291,"briefTitle":292,"officialTitle":293,"acronym":4,"eligibilityCriteria":294,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":295,"enrollmentInfo":296,"targetDuration":4,"studyType":22,"phases":298,"briefSummary":299,"conditions":300,"keywords":303,"overallStatus":142,"whyStopped":4,"lastUpdateSubmitDate":307,"lastUpdatePostDateStruct":308,"startDateStruct":310,"completionDateStruct":312,"leadSponsor":314,"locationsCount":85},"100556662","phase-4-efficacy-and-safety-of-probiotics-combined-with-enteric-coated-budesonide-capsules-in-patients-with-primary-iga-nephropathy-100556662","NCT06528015","Efficacy and Safety of Probiotics Combined With Enteric-coated Budesonide Capsules in Patients With Primary IgA Nephropathy","Efficacy and Safety of Probiotics Combined With Enteric-coated Budesonide Capsules in Patients With Primary IgA Nephropathy: a Prospective, Multicenter, Randomized, Single-blind, Placebo-controlled Clinical Trial","Inclusion Criteria:\n\n1. Adult age: 18\\~70 years old;\n2. Renal biopsy-confirmed primary IgA nephropathy;\n3. 24-h urine protein excretion ≥ 0.75g, or urinary protein creatinine ratio (UPCR) ≥ 0.5g\u002Fg;\n4. eGFR ≥ 30mL\u002Fmin\u002F1.73m\\^2 estimated with the Chronic Kidney Disease Epidemiology Collaboration 2009 formula (CKD-EPI2009);\n5. Fertile men and female of childbearing age need to use highly effective contraceptive measures from the time they sign informed consent to the end of the safety follow-up period;\n6. Sign the informed consent, understand and agree to comply with the requirements of the study and the trial procedures.\n\nExclusion Criteria:\n\n1. Secondary form of IgA nephropathy or any non-IgA nephropathy Glomerulonephritis;\n2. Specific types of IgA nephropathy (including minor lesions with mesangial IgA deposition, rapidly progressive and crescentic IgA nephropathy, etc.) and other glomerular diseases (such as diabetic nephropathy, etc.);\n3. 24-h urine protein excretion \\>5g;\n4. Renal biopsy showed crescent ≥25%;\n5. A history of severe gastrointestinal disease (such as active peptic ulcer disease, active gastrointestinal bleeding, gastrointestinal perforation, inflammatory bowel disease, and chronic diarrhea) or a history of gastrointestinal surgery;\n6. Complicated with malignant tumors (diagnosed within the past 5 years), cerebral infarction, cerebral hemorrhage, myocardial infarction, arrhythmia, heart failure and other serious primary diseases;\n7. The presence of severe chronic or active infections (including but not limited to tuberculosis) that require systemic antimicrobial, antifungal, antiviral, or antiparasitic treatment;\n8. A history of cirrhosis;\n9. Severe osteoporosis requiring treatment;\n10. Received organ transplants;\n11. Glaucoma or cataracts who currently require clinical treatment;\n12. Diagnosed with uncontrolled mental illness;\n13. Participants with poorly controlled type 1 or type 2 diabetes (glycated haemoglobin \\[HbA1c\\] \\>8%;\n14. Laboratory tests for abnormal liver function (ALT and\u002For AST\\> 2 times the upper normal limit, ALP\\> 2.5 times the upper normal limit);\n15. The blood total cholesterol was seriously abnormal (\\>12.92mmol\u002FL);\n16. Human immunodeficiency virus antibody positive, treponema pallidum antibody positive, hepatitis B surface antigen positive, hepatitis C antibody positive;\n17. Currently using a potent inhibitor of cytochrome P4503A4 (CYP3A4) and cannot be discontinued during the study;\n18. Known allergy or intolerance to ACEI, ARB, budesonide or any component of the investigational drug formulation;\n19. Use of antibiotics, glucocorticoids or other immunosuppressants, foods and medicines containing probiotics\u002Fprebiotics within the past 3 months;\n20. Pregnant or lactating participants;\n21. Also accepting participants from other clinical trials;\n22. Participants who have been determined by the researchers to be unable to complete on time.","70 Years",{"count":297,"type":21},206,[24],"The goal of this clinical trial is to evaluate the efficacy and safety of probiotics combined with enteric-coated budesonide capsule in patients with IgA nephropathy on the basis of optimized RAS blockade therapy, and to explore the correlation between the efficacy of probiotics combined with enteric-coated budesonide capsule in the treatment of primary IgA nephropathy and intestinal homeostasis.\n\nThe main questions it aims to answer are:\n\nDose probiotics combined with enteric-coated budesonide capsule provide a durable reduction in urine protein creatinine ratio (UPCR) in participants, compared with probiotics placebo combined with enteric-coated budesonide capsule? What medical problems do participants have when taking probiotics combined with enteric-coated budesonide capsule?\n\nParticipants will:\n\nTake probiotics combined with enteric-coated budesonide capsules or probiotics placebo combined with enteric-coated budesonide capsules every day for 9.5 month Participate in center site follow-up visits for 13 times Keep a diary of their symptoms and outcomes",[301,28,302],"Glomerulonephritis, IGA","Budesonide",[304,305,306],"enteric-coated budesonide capsules","probiotic","primary IgA nephropathy","2024-07-29",{"date":309,"type":35},"2024-07-30",{"date":311,"type":21},"2024-07",{"date":313,"type":21},"2028-12-31",{"name":315,"class":41},"Gang Xu"]